WallStSmart

Colgate-Palmolive Company (CL)vsNu Skin Enterprises Inc (NUS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Colgate-Palmolive Company generates 1430% more annual revenue ($21.05B vs $1.38B). CL leads profitability with a 9.7% profit margin vs -15.7%. NUS appears more attractively valued with a PEG of 0.78. CL earns a higher WallStSmart Score of 54/100 (C-).

CL

Buy

54

out of 100

Grade: C-

Growth: 3.3Profit: 8.5Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 4.21

NUS

Hold

47

out of 100

Grade: D+

Growth: 2.0Profit: 4.5Value: 7.7Quality: 7.5
Piotroski: 5/9Altman Z: 4.45
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLUndervalued (+8.4%)

Margin of Safety

+8.4%

Fair Value

$99.45

Current Price

$92.06

$7.39 discount

UndervaluedFair: $99.45Overvalued
NUSUndervalued (+53.3%)

Margin of Safety

+53.3%

Fair Value

$21.79

Current Price

$4.79

$17.00 discount

UndervaluedFair: $21.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CL4 strengths · Avg: 9.3/10
Return on EquityProfitability
863.1%10/10

Every $100 of equity generates 863 in profit

Altman Z-ScoreHealth
4.2110/10

Safe zone — low bankruptcy risk

Market CapQuality
$71.91B9/10

Large-cap with strong market position

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

NUS3 strengths · Avg: 9.3/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
4.4510/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.788/10

Growing faster than its price suggests

Areas to Watch

CL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.774/10

Expensive relative to growth rate

P/E RatioValuation
36.2x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Price/BookValuation
306.9x2/10

Trading at 306.9x book value

NUS4 concerns · Avg: 2.5/10
Market CapQuality
$230.73M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.9%3/10

ROE of 6.9% — below average capital efficiency

Revenue GrowthGrowth
-17.1%2/10

Revenue declined 17.1%

EPS GrowthGrowth
-98.2%2/10

Earnings declined 98.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : CL

The strongest argument for CL centers on Return on Equity, Altman Z-Score, Market Cap.

Bull Case : NUS

The strongest argument for NUS centers on Price/Book, Altman Z-Score, PEG Ratio. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bear Case : CL

The primary concerns for CL are PEG Ratio, P/E Ratio, Revenue Growth. Debt-to-equity of 33.29 is elevated, increasing financial risk.

Bear Case : NUS

The primary concerns for NUS are Market Cap, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

CL profiles as a value stock while NUS is a turnaround play — different risk/reward profiles.

NUS carries more volatility with a beta of 0.97 — expect wider price swings.

CL is growing revenue faster at 4.9% — sustainability is the question.

CL generates stronger free cash flow (867M), providing more financial flexibility.

Bottom Line

CL scores higher overall (54/100 vs 47/100). NUS offers better value entry with a 53.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Colgate-Palmolive Company

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Colgate-Palmolive Company is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. It specializes in the production, distribution and provision of household, health care, personal care and veterinary products.

Visit Website →

Nu Skin Enterprises Inc

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Nu Skin Enterprises, Inc. develops and distributes wellness and personal care products globally. The company is headquartered in Provo, Utah.

Visit Website →

Want to dig deeper into these stocks?